A Phase 1 interventional study of Z7200 without oral activated charcoal and Symbicort Turbohaler without oral activated charcoal in Asthma, sponsored by Zambon SpA. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-02-23.
Sponsored by Zambon SpA · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 110 studies testing budesonide in Asthma — 6 open to participants now, 6 under way, 3 of them phase 3. Budesonide · Asthma.
Among the 110 studies testing budesonide in Asthma, this one is the 68th largest by enrollment of the 108 interventional ones that give a count, is one of 2 that started in 2014, is one of 10 in phase 1, and was the 78th registered.
4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.
Browse Asthma studies →6 of the 110 studies testing budesonide in Asthma are open now, in 5 countries. Recruiting first, the newest first:
University of Miami · Sites in United States
Ages 18–75
Massachusetts General Hospital · Sites in United States
Ages 18–54
University of KwaZulu · Sites in South Africa
Ages 6–18
Franciscus Gasthuis · Sites in Netherlands
Ages 18+
University of British Columbia · Sites in Canada
Ages 19–49
By country, each count listing its studies:
Budesonide: first FDA approval 1994 (RHINOCORT), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
110 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 6 · Phase 3 51 · Phase 4 33
First in 1991; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 90 is above the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 124 across the 108 interventional studies. Of the 94 that completed or were terminated, 35 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
64 of 110 have an industry lead sponsor. The 10 most frequent:
Zambon SpA is the lead sponsor of 23 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.
Zambon SpA has 4 studies filed under Asthma — fewer than ten, so there is no comparison to draw.
1 of the studies testing budesonide in Asthma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07166939Massachusetts General Hospital45th Multicenter Airway Research Collaboration | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 110 studies testing budesonide in Asthma, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective was:
The secondary objectives were:
This was a single center, open label, randomized, five-period crossover, single-dose study in healthy volunteers aged 18 to 45 years. A total of 90 volunteers were enrolled, with 9 subjects in each of the 10 treatment sequences.
The study consisted of 5 treatment periods, each lasting approximately 48h, separated by a washout period of a minimum of 5 days. RS01 and/or Symbicort Turbohaler device use training was provided on Day -1 and Day 1 of each treatment period. Subjects were screened for eligibility to participate in the study -28 to -2 days prior to the first treatment period, and were randomized to one of 10 treatment sequencies containing the following 5 treatment arms on Day 1 of the first treatment period:
Treatment A: Z7200 without oral activated charcoal* Treatment B1: Symbicort 1 without oral activated charcoal* Treatment B2: Symbicort 2 without oral activated charcoal* Treatment C: Z7200 with oral activated charcoal** Treatment D: Symbicort with oral activated charcoal**
Subjects were admitted to the clinical unit at 8.00 on the morning of Day -1, and were dosed on the morning of Day 1 following an overnight fast (minimum of 8h). On Day 2, following collection of the 24-h PK blood sample, subjects were discharged.
* Subjects who received treatments A, B1 and B2 rinsed their mouth vigorously with 50 mL water for 3 to 5 sec immediately after the second inhalation.
** A charcoal blockade was used to prevent absorption from oropharyngeal and GI tract, in order to assess the pulmonary deposition of budesonide and formoterol, with periods performed without a charcoal blockade allowing the assessment of the total systemic exposure to the drug.
Main Inclusion Criteria:
Main Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects were dosed on Day 1 of each treatment period with one of the following 5 treatments according to the randomization schedule using a Williams Latin Square design: 1. Treatment A: Z7200 without oral activated charcoal 2. Treatment B1: Symbicort 1 without oral activated charcoal 3. Treatment B2: Symbicort 2 without oral activated charcoal 4. Treatment C: Z7200 with oral activated charcoal 5. Treatment D: Symbicort with oral activated charcoal A washout period of a minimum of 5 days followed treatment periods 1 to 4. Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2.
Drug: Z7200 without oral activated charcoal · Drug: Symbicort Turbohaler without oral activated charcoal · Drug: Z7200 with oral activated charcoal · Drug: Symbicort Turbohaler with oral activated charcoal
Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design: 1. Treatment A: Z7200 without oral activated charcoal 2. Treatment B1: Symbicort 1 without oral activated charcoal 3. Treatment B2: Symbicort 2 without oral activated charcoal 4. Treatment C: Z7200 with oral activated charcoal 5. Treatment D: Symbicort with oral activated charcoal A washout period of a minimum of 5 day followed treatment periods 1 to 4. Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2.
Drug: Z7200 without oral activated charcoal · Drug: Symbicort Turbohaler without oral activated charcoal · Drug: Z7200 with oral activated charcoal · Drug: Symbicort Turbohaler with oral activated charcoal
Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design: 1. Treatment A: Z7200 without oral activated charcoal 2. Treatment B1: Symbicort 1 without oral activated charcoal 3. Treatment B2: Symbicort 2 without oral activated charcoal 4. Treatment C: Z7200 with oral activated charcoal 5. Treatment D: Symbicort with oral activated charcoal A washout period of a minimum of 5 day followed treatment periods 1 to 4. Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2.
Drug: Z7200 without oral activated charcoal · Drug: Symbicort Turbohaler without oral activated charcoal · Drug: Z7200 with oral activated charcoal · Drug: Symbicort Turbohaler with oral activated charcoal
Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design: 1. Treatment A: Z7200 without oral activated charcoal 2. Treatment B1: Symbicort 1 without oral activated charcoal 3. Treatment B2: Symbicort 2 without oral activated charcoal 4. Treatment C: Z7200 with oral activated charcoal 5. Treatment D: Symbicort with oral activated charcoal A washout period of a minimum of 5 day followed treatment periods 1 to 4. Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2.
Drug: Z7200 without oral activated charcoal · Drug: Symbicort Turbohaler without oral activated charcoal · Drug: Z7200 with oral activated charcoal · Drug: Symbicort Turbohaler with oral activated charcoal
Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design: 1. Treatment A: Z7200 without oral activated charcoal 2. Treatment B1: Symbicort 1 without oral activated charcoal 3. Treatment B2: Symbicort 2 without oral activated charcoal 4. Treatment C: Z7200 with oral activated charcoal 5. Treatment D: Symbicort with oral activated charcoal A washout period of a minimum of 5 day followed treatment periods 1 to 4. Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2.
Drug: Z7200 without oral activated charcoal · Drug: Symbicort Turbohaler without oral activated charcoal · Drug: Z7200 with oral activated charcoal · Drug: Symbicort Turbohaler with oral activated charcoal
Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design: 1. Treatment A: Z7200 without oral activated charcoal 2. Treatment B1: Symbicort 1 without oral activated charcoal 3. Treatment B2: Symbicort 2 without oral activated charcoal 4. Treatment C: Z7200 with oral activated charcoal 5. Treatment D: Symbicort with oral activated charcoal A washout period of a minimum of 5 day followed treatment periods 1 to 4. Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2.
Drug: Z7200 without oral activated charcoal · Drug: Symbicort Turbohaler without oral activated charcoal · Drug: Z7200 with oral activated charcoal · Drug: Symbicort Turbohaler with oral activated charcoal
Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design: 1. Treatment A: Z7200 without oral activated charcoal 2. Treatment B1: Symbicort 1 without oral activated charcoal 3. Treatment B2: Symbicort 2 without oral activated charcoal 4. Treatment C: Z7200 with oral activated charcoal 5. Treatment D: Symbicort with oral activated charcoal A washout period of a minimum of 5 day followed treatment periods 1 to 4. Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2.
Drug: Z7200 without oral activated charcoal · Drug: Symbicort Turbohaler without oral activated charcoal · Drug: Z7200 with oral activated charcoal · Drug: Symbicort Turbohaler with oral activated charcoal
Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design: 1. Treatment A: Z7200 without oral activated charcoal 2. Treatment B1: Symbicort 1 without oral activated charcoal 3. Treatment B2: Symbicort 2 without oral activated charcoal 4. Treatment C: Z7200 with oral activated charcoal 5. Treatment D: Symbicort with oral activated charcoal A washout period of a minimum of 5 day followed treatment periods 1 to 4. Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2.
Drug: Z7200 without oral activated charcoal · Drug: Symbicort Turbohaler without oral activated charcoal · Drug: Z7200 with oral activated charcoal · Drug: Symbicort Turbohaler with oral activated charcoal
Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design: 1. Treatment A: Z7200 without oral activated charcoal 2. Treatment B1: Symbicort 1 without oral activated charcoal 3. Treatment B2: Symbicort 2 without oral activated charcoal 4. Treatment C: Z7200 with oral activated charcoal 5. Treatment D: Symbicort with oral activated charcoal A washout period of a minimum of 5 day followed treatment periods 1 to 4. Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2.
Drug: Z7200 without oral activated charcoal · Drug: Symbicort Turbohaler without oral activated charcoal · Drug: Z7200 with oral activated charcoal · Drug: Symbicort Turbohaler with oral activated charcoal
Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design: 1. Treatment A: Z7200 without oral activated charcoal 2. Treatment B1: Symbicort 1 without oral activated charcoal 3. Treatment B2: Symbicort 2 without oral activated charcoal 4. Treatment C: Z7200 with oral activated charcoal 5. Treatment D: Symbicort with oral activated charcoal A washout period of a minimum of 5 day followed treatment periods 1 to 4. Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2.
Drug: Z7200 without oral activated charcoal · Drug: Symbicort Turbohaler without oral activated charcoal · Drug: Z7200 with oral activated charcoal · Drug: Symbicort Turbohaler with oral activated charcoal
Drug pages: Budesonide · Formoterol
160 ug budesonide and 4.5 ug formoterol fumarate dihydrate, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25 ug/inhalation, using an RS01 inhaler (Treatment A).
Also known as: budesonide/formoterol
Drug pages: Budesonide · Formoterol
320 ug budesonide and 9 ug formoterol fumarate dihydrate, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation (Treatments B1 and B2).
Also known as: budesonide/formoterol
Drug page: Charcoal
160 ug budesonide and 4.5 ug formoterol fumarate dihydrate, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25 ug/inhalation, using an RS01 inhaler with a charcoal blockade (Treatment C).
Also known as: budesonide/formoterol with coadministration of charcoal
Drug page: Charcoal
320 ug budesonide and 9 ug formoterol fumarate dihydrate, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation from a Symbicort Turbohaler, with charcoal blockade (Treatment D).
Also known as: budesonide/formoterol with coadministration of charcoal
AUC0-t of Budesonide With and Without Charcoal Blockade
Area under the plasma concentration-time curve from time zero to the last detectable level calculations were performed using the linear trapezoidal rule. Participants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.
Time frame: 0-24h (0, 2, 5, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, 720, and 1440 min)
AUC0-t of Formoterol With and Without Charcoal Blockade
Area under the plasma concentration-time curve from time zero to the last detectable level calculations were performed using the linear trapezoidal rule. Participants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.
Time frame: 0-24h (0, 2, 5, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, 720, and 1440 min)
Cmax of Budesonide With and Without Charcoal Blockade
Maximum plasma level of budesonide with and without charcoal blockade. Participants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.
Time frame: 0-24h (0, 2, 5, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, 720, and 1440 min)
Cmax of Formoterol With and Without Charcoal Blockade
Maximum plasma level of formoterol with and without charcoal blockade. Participants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.
Time frame: 0-24h (0, 2, 5, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, 720, and 1440 min)
AUC0-30 of Budesonide With and Without Charcoal Blockade.
Area under the plasma concentration-time curve from time zero to 30 minutes calculations were performed using the linear trapezoidal rule. Participants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.
Time frame: 0-30 min (0, 2, 5, 10, 15, 20, and 30 min)
AUC0-30 of Formoterol With and Without Charcoal Blockade.
Area under the plasma concentration-time curve from time zero to 30 minutes calculations were performed using the linear trapezoidal rule. Participants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.
Time frame: 0-30 min (0, 2, 5, 10, 15, 20, and 30 min)
AUC0-∞ of Budesonide With and Without Charcoal Blockade
Area under the plasma concentration-time curve from time zero to infinity calculations were performed using the linear trapezoidal rule. Participants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.
Time frame: 0-24h (0, 2, 5, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, 720, and 1440 min)
AUC0-∞ of Formoterol With and Without Charcoal Blockade
Area under the plasma concentration-time curve from time zero to infinity calculations were performed using the linear trapezoidal rule. Participants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.
Time frame: 0-24h (0, 2, 5, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, 720, and 1440 min)
Tmax for Budesonide With and Without Charcoal Blockade
Time at which the maximum plasma level (Cmax) occurred with and without charcoal blockade. Participants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.
Time frame: 0-24h (0, 2, 5, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, 720, and 1440 min)
Tmax for Formoterol With and Without Charcoal Blockade
Time at which the maximum plasma level (Cmax) occurred with and without charcoal blockade. Participants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.
Time frame: 0-24h (0, 2, 5, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, 720, and 1440 min)
t1/2 for Budesonide With and Without Charcoal Blockade
Apparent elimination half-life calculated as 0.693/lambda zeta, with and without charcoal blockade. Participants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.
Time frame: 0-24h (0, 2, 5, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, 720, and 1440 min)
t1/2 for Formoterol With and Without Charcoal Blockade
Apparent elimination half-life calculated as 0.693/lambda zeta, with and without charcoal blockade. Participants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.
Time frame: 0-24h (0, 2, 5, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, 720, and 1440 min)
Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1)
FEV1 refers to the volume of air that an individual can exhale during a forced breath in 1 second. Participants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together. and Symbicort 2, together. Please note that, within the safety population, 90 subjects received Treatment B. This would mean that theorically 180 participants received Symbicort 1 and Symbicort 2, together. But some subjects were excluded from the statistical analysis for various reasons so that the total number included in the statistical anlysis for treatment B is 174.
Time frame: At 75 min (1.25 hours) post-dose
Change From Baseline in the Ratio of Forced Expiratory Volume in 1 Second to Forced Vital Capacity (FEV1/FVC)
FVC = Forced vital capacity. It is the full amount of air that can be exhaled with effort in a complete breath. FEV1/FVC = Tiffenau-Pinelli Index. This parameter represents the measurement of the amount of air an individual can forcefully exhale from his/her lungs. Participants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together. Please note that, within the safety population, 90 subjects received Treatment B. This would mean that theorically 180 participants received Symbicort 1 and Symbicort 2, together. But 6 subjects were excluded from the statistical analysis for various reasons so that the total number included in the statistical anlysis for treatment B is 174.
Time frame: At 75 min (1.25 hours) post-dose
Change From Baseline in Peak Expiratory Flow Rate (PEFR)
PEFR is the highest rate at which gases can be expelled from the lungs via an open mouth. Its measurement is a simple procedure in which an individual takes a full inspiration and blows out as forcibly as possible into an instrument called a peak flow meter, which measures the maximal gas flow in an exhalation in liters per minute. Participants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.Please note that, within the safety population, 90 subjects received Treatment B. This would mean that theorically 180 participants received Symbicort 1 and Symbicort 2, together. But 6 subjects were excluded from the statistical analysis for various reasons so that the total number included in the statistical anlysis for treatment B is 174.
Time frame: At 75 min (1.25 hours) post-dose
Subjects were screened for eligibility -28 to -2 days prior to the first treatment period. On Day -1 of the first treatment period, i.d. before randomization, subjects were trained on both the RS01 and Symbicort Turbohaler devices.
| Milestone | A-B1-B2-C-D | B1-C-A-D-B2 | C-D-B1-B2-A | D-B2-C-A-B1 | B2-A-D-B1-C | D-C-B2-B1-A | B2-D-A-C-B1 | A-B2-B1-D-C | B1-A-C-B2-D | C-B1-D-A-B2 |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 |
| A | 9 | 6 | 8 | 8 | 9 | 8 | 8 | 9 | 9 | 9 |
| B1 | 9 | 9 | 9 | 8 | 9 | 9 | 9 | 9 | 9 | 9 |
| B2 | 9 | 6 | 9 | 9 | 9 | 9 | 9 | 9 | 8 | 9 |
| C | 9 | 8 | 9 | 8 | 9 | 9 | 9 | 9 | 9 | 9 |
| D | 9 | 6 | 9 | 9 | 9 | 9 | 9 | 9 | 8 | 9 |
| Completed | 9 | 6 | 8 | 8 | 9 | 8 | 8 | 9 | 8 | 9 |
| Not completed | 0 | 3 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 2 | 0 | 1 | 0 | 1 | 1 | 0 | 1 | 0 |
| Withdrew: Physician decision | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Area under the plasma concentration-time curve from time zero to the last detectable level calculations were performed using the linear trapezoidal rule. Participants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.
| pg*h/mL | Treatment A | Treatment B | Treatment C | Treatment D |
|---|---|---|---|---|
| AUC0-t of Budesonide With and Without Charcoal Blockade | 1870 ± 20.2 | 1360 ± 49.4 | 1810 ± 22.3 | 1330 ± 52.3 |
Area under the plasma concentration-time curve from time zero to the last detectable level calculations were performed using the linear trapezoidal rule. Participants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.
| pg*h/mL | Treatment A | Treatment B | Treatment C | Treatment D |
|---|---|---|---|---|
| AUC0-t of Formoterol With and Without Charcoal Blockade | 47.4 ± 26.0 | 40.1 ± 58.6 | 44.7 ± 26.8 | 34.5 ± 78.1 |
Maximum plasma level of budesonide with and without charcoal blockade. Participants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.
| pg/mL | Treatment A | Treatment B | Treatment C | Treatment D |
|---|---|---|---|---|
| Cmax of Budesonide With and Without Charcoal Blockade | 1040 ± 67.7 | 482 ± 63.4 | 1090 ± 78.9 | 542 ± 62.4 |
Maximum plasma level of formoterol with and without charcoal blockade. Participants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.
| pg/mL | Treatment A | Treatment B | Treatment C | Treatment D |
|---|---|---|---|---|
| Cmax of Formoterol With and Without Charcoal Blockade | 11.9 ± 38.6 | 9.53 ± 57.5 | 12.4 ± 35.5 | 10.6 ± 58.4 |
Area under the plasma concentration-time curve from time zero to 30 minutes calculations were performed using the linear trapezoidal rule. Participants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.
| pg*h/mL | Treatment A | Treatment B | Treatment C | Treatment D |
|---|---|---|---|---|
| AUC0-30 of Budesonide With and Without Charcoal Blockade. | 324 ± 36.5 | 174 ± 62.0 | 342 ± 38.3 | 193 ± 63.4 |
Area under the plasma concentration-time curve from time zero to 30 minutes calculations were performed using the linear trapezoidal rule. Participants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.
| pg*h/mL | Treatment A | Treatment B | Treatment C | Treatment D |
|---|---|---|---|---|
| AUC0-30 of Formoterol With and Without Charcoal Blockade. | 3.85 ± 33.0 | 3.12 ± 54.4 | 4.00 ± 32.1 | 3.35 ± 58.2 |
Area under the plasma concentration-time curve from time zero to infinity calculations were performed using the linear trapezoidal rule. Participants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.
| pg*h/mL | Treatment A | Treatment B | Treatment C | Treatment D |
|---|---|---|---|---|
| AUC0-∞ of Budesonide With and Without Charcoal Blockade | 1980 ± 20.5 | 1450 ± 48.8 | 1900 ± 22.4 | 1410 ± 50.1 |
Area under the plasma concentration-time curve from time zero to infinity calculations were performed using the linear trapezoidal rule. Participants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.
| pg*h/mL | Treatment A | Treatment B | Treatment C | Treatment D |
|---|---|---|---|---|
| AUC0-∞ of Formoterol With and Without Charcoal Blockade | 56.0 ± 28.2 | 49.8 ± 57.1 | 54.5 ± 27.7 | 45.2 ± 61.6 |
Time at which the maximum plasma level (Cmax) occurred with and without charcoal blockade. Participants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.
| hours | Treatment A | Treatment B | Treatment C | Treatment D |
|---|---|---|---|---|
| Tmax for Budesonide With and Without Charcoal Blockade | 0.08 (0.03 to 0.75) | 0.25 (0.03 to 1.50) | 0.08 (0.03 to 0.75) | 0.25 (0.03 to 1.00) |
Time at which the maximum plasma level (Cmax) occurred with and without charcoal blockade. Participants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.
| hours | Treatment A | Treatment B | Treatment C | Treatment D |
|---|---|---|---|---|
| Tmax for Formoterol With and Without Charcoal Blockade | 0.08 (0.08 to 0.20) | 0.08 (0.04 to 0.25) | 0.08 (0.03 to 0.17) | 0.08 (0.08 to 0.17) |
Apparent elimination half-life calculated as 0.693/lambda zeta, with and without charcoal blockade. Participants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.
| hours | Treatment A | Treatment B | Treatment C | Treatment D |
|---|---|---|---|---|
| t1/2 for Budesonide With and Without Charcoal Blockade | 2.90 ± 17.0 | 2.94 ± 19.8 | 2.79 ± 17.0 | 2.80 ± 15.8 |
Apparent elimination half-life calculated as 0.693/lambda zeta, with and without charcoal blockade. Participants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.
| hours | Treatment A | Treatment B | Treatment C | Treatment D |
|---|---|---|---|---|
| t1/2 for Formoterol With and Without Charcoal Blockade | 9.57 ± 29.3 | 9.33 ± 35.2 | 10.09 ± 29.8 | 9.15 ± 33.6 |
FEV1 refers to the volume of air that an individual can exhale during a forced breath in 1 second. Participants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together. and Symbicort 2, together. Please note that, within the safety population, 90 subjects received Treatment B. This would mean that theorically 180 participants received Symbicort 1 and Symbicort 2, together. But some subjects were excluded from the statistical analysis for various reasons so that the total number included in the statistical anlysis for treatment B is 174.
| liters | Treatment A | Treatment B | Treatment C | Treatment D |
|---|---|---|---|---|
| Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) | 0.2 ± 0.2 | 0.2 ± 0.2 | 0.2 ± 0.2 | 0.2 ± 0.2 |
FVC = Forced vital capacity. It is the full amount of air that can be exhaled with effort in a complete breath. FEV1/FVC = Tiffenau-Pinelli Index. This parameter represents the measurement of the amount of air an individual can forcefully exhale from his/her lungs. Participants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together. Please note that, within the safety population, 90 subjects received Treatment B. This would mean that theorically 180 participants received Symbicort 1 and Symbicort 2, together. But 6 subjects were excluded from the statistical analysis for various reasons so that the total number included in the statistical anlysis for treatment B is 174.
| ratio | Treatment A | Treatment B | Treatment C | Treatment D |
|---|---|---|---|---|
| Change From Baseline in the Ratio of Forced Expiratory Volume in 1 Second to Forced Vital Capacity (FEV1/FVC) | 3.7 ± 3.0 | 3.6 ± 3.4 | 3.2 ± 3.1 | 3.8 ± 3.2 |
PEFR is the highest rate at which gases can be expelled from the lungs via an open mouth. Its measurement is a simple procedure in which an individual takes a full inspiration and blows out as forcibly as possible into an instrument called a peak flow meter, which measures the maximal gas flow in an exhalation in liters per minute. Participants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.Please note that, within the safety population, 90 subjects received Treatment B. This would mean that theorically 180 participants received Symbicort 1 and Symbicort 2, together. But 6 subjects were excluded from the statistical analysis for various reasons so that the total number included in the statistical anlysis for treatment B is 174.
| L/min | Treatment A | Treatment B | Treatment C | Treatment D |
|---|---|---|---|---|
| Change From Baseline in Peak Expiratory Flow Rate (PEFR) | 22.2 ± 48.9 | 20.5 ± 38.7 | 24.8 ± 35.5 | 19.2 ± 38.9 |
Collected over Throughout the study till the end of trial assessment, which was completed on Day 2 of last treatment period (up to 6 weeks).. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment A | 0/84 (0%) | 0/84 (0%) | 16/84 (19%) |
| Treatment B | 0/90 (0%) | 0/90 (0%) | 20/90 (22.2%) |
| Treatment C | 0/88 (0%) | 0/88 (0%) | 6/88 (6.8%) |
| Treatment D | 0/86 (0%) | 0/86 (0%) | 15/86 (17.4%) |
| Event | Treatment A | Treatment B | Treatment C | Treatment D |
|---|---|---|---|---|
| HeadacheNervous system disorders | 5/84 | 8/90 | 2/88 | 7/86 |
| RhinorrhoeaRespiratory, thoracic and mediastinal disorders | 0/84 | 2/90 | 0/88 | 0/86 |
| ParaesthesiaNervous system disorders | 1/84 | 0/90 | 0/88 | 0/86 |
| Oral PainGastrointestinal disorders | 1/84 | 0/90 | 0/88 | 0/86 |
| ToothacheGastrointestinal disorders | 1/84 | 0/90 | 0/88 | 0/86 |
| Catheter site related reactionGeneral disorders | 1/84 | 1/90 | 0/88 | 0/86 |
| Chest discomfortGeneral disorders | 1/84 | 1/90 | 0/88 | 0/86 |
| Vessel puncture site swellingGeneral disorders | 1/84 | 0/90 | 0/88 | 0/86 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 1/84 | 0/90 | 0/88 | 0/86 |
| Eosinophil count increasedInvestigations | 1/84 | 1/90 | 1/88 | 0/86 |
Safety population: All subjects who received at least one dose (2 inhalations) of investigational medicinal product.
| Age, Categorical(Participants) | A-B1-B2-C-D | B1-C-A-D-B2 | C-D-B1-B2-A | D-B2-C-A-B1 | B2-A-D-B1-C | D-C-B2-B1-A | B2-D-A-C-B1 | A-B2-B1-D-C | B1-A-C-B2-D | C-B1-D-A-B2 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 90 |
| >=65 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | A-B1-B2-C-D | B1-C-A-D-B2 | C-D-B1-B2-A | D-B2-C-A-B1 | B2-A-D-B1-C | D-C-B2-B1-A | B2-D-A-C-B1 | A-B2-B1-D-C | B1-A-C-B2-D | C-B1-D-A-B2 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 29.0 ± 7.9 | 24.7 ± 6.5 | 27.2 ± 6.0 | 28.1 ± 7.4 | 26.3 ± 7.6 | 29.8 ± 8.5 | 28.0 ± 7.6 | 28.3 ± 5.9 | 27.8 ± 8.9 | 36.2 ± 5.0 | 28.5 ± 7.4 |
| Sex: Female, Male(Participants) | A-B1-B2-C-D | B1-C-A-D-B2 | C-D-B1-B2-A | D-B2-C-A-B1 | B2-A-D-B1-C | D-C-B2-B1-A | B2-D-A-C-B1 | A-B2-B1-D-C | B1-A-C-B2-D | C-B1-D-A-B2 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 3 | 5 | 4 | 1 | 2 | 5 | 5 | 3 | 5 | 4 | 37 |
| Male | 6 | 4 | 5 | 8 | 7 | 4 | 4 | 6 | 4 | 5 | 53 |
| Race (NIH/OMB)(Participants) | A-B1-B2-C-D | B1-C-A-D-B2 | C-D-B1-B2-A | D-B2-C-A-B1 | B2-A-D-B1-C | D-C-B2-B1-A | B2-D-A-C-B1 | A-B2-B1-D-C | B1-A-C-B2-D | C-B1-D-A-B2 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 3 | 5 |
| White | 7 | 9 | 9 | 9 | 8 | 8 | 7 | 9 | 8 | 6 | 80 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 2 |
| Region of Enrollment(participants) | A-B1-B2-C-D | B1-C-A-D-B2 | C-D-B1-B2-A | D-B2-C-A-B1 | B2-A-D-B1-C | D-C-B2-B1-A | B2-D-A-C-B1 | A-B2-B1-D-C | B1-A-C-B2-D | C-B1-D-A-B2 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| United Kingdom | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 90 |
The record gives a start of Sep 2014, a primary completion of Feb 2015 and a completion of Feb 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2022, 6 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Budesonide · Formoterol · Charcoal